Amphotericin B Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel (Direct, Indirect), By End Use (Systemic Fungal Infections, Candidiasis, Aspergillosis, Mucormycosis, Leishmaniasis, Others), By Region and Competition, 2020-2030F

Market Overview

Global Amphotericin B Market was valued at USD 69.41 Million in 2024 and is expected to reach USD 105.54 Million by 2030 with a CAGR of 2.91% during the forecast period. The global Amphotericin B market is witnessing steady growth, primarily driven by the rising incidence of life-threatening fungal infections and the growing population of immunocompromised patients worldwide. Amphotericin B, a polyene antifungal agent, remains one of the most effective treatments for severe systemic mycoses, including cryptococcal meningitis, aspergillosis, mucormycosis, and candidiasis. Despite the availability of newer antifungal agents, Amphotericin B continues to hold significant therapeutic relevance, especially in hospital settings and cases of multidrug resistance.

One of the key growth drivers is the increasing prevalence of opportunistic fungal infections among individuals with weakened immune systems, such as those undergoing chemotherapy, organ transplantation, or living with HIV/AIDS. The recent rise in mucormycosis cases, particularly during the COVID-19 pandemic in certain countries, has further elevated the demand for Amphotericin B. Additionally, advancements in liposomal and lipid complex formulations have improved drug tolerability and reduced nephrotoxicity, enhancing clinical adoption. Expanding healthcare access and rising awareness in developing economies are also contributing to greater use of antifungal therapies, boosting market potential.

Despite its efficacy, the market faces several challenges. The high cost of liposomal formulations limits affordability and accessibility, especially in low- and middle-income countries. Moreover, the drug’s known side effect profile, including nephrotoxicity and infusion-related reactions, often requires hospitalization and close monitoring, thereby increasing the overall treatment burden. Regulatory complexities associated with the manufacturing of sterile injectable formulations further contribute to supply chain constraints and production costs.

Key Market Drivers

Growth in Healthcare Industry

The steady expansion of the global healthcare industry is a key factor driving the growth of the Amphotericin B market. The global hospitals market is projected to generate revenue of USD 4.41 trillion by 2025. In the United States, hospitals are making significant investments in telemedicine technologies to expand access to remote healthcare services, particularly for patients in rural regions. As healthcare systems evolve and medical infrastructure strengthens across both developed and emerging economies, there is a growing emphasis on effective treatment of life-threatening fungal infections, an area where Amphotericin B remains a gold standard. Known for its potent antifungal properties, Amphotericin B is widely used in the management of systemic mycoses, particularly in immunocompromised patients, such as those with HIV/AIDS, cancer, or undergoing organ transplants.

Increasing healthcare expenditure globally is facilitating broader access to advanced antifungal therapies. Germany recorded the highest current healthcare expenditure among EU member states in 2022, amounting to USD 538.12 billion. In terms of healthcare spending as a share of GDP, Germany (12.6%), France (11.9%), and Austria (11.2%) reported the highest ratios within the European Union during the same year. Governments and private healthcare providers are allocating larger budgets to improve hospital facilities, diagnostic capabilities, and treatment protocols, all of which contribute to the rising use of Amphotericin B. This is particularly evident in tertiary care centers where severe fungal infections are more likely to be treated with high-efficacy drugs.

Surge in Technological Advancements

The global Amphotericin B market is witnessing steady growth, significantly propelled by the surge in technological advancements across pharmaceutical research, drug delivery systems, and production methodologies. These innovations are addressing key challenges traditionally associated with Amphotericin B, such as toxicity, poor solubility, and limited patient compliance, thereby enhancing its therapeutic potential and broadening its application scope.

One of the most impactful developments has been the advancement of lipid-based and liposomal formulations of Amphotericin B. Through the strategic selection of lipids and the incorporation of co-solvents or surfactants, researchers have enhanced drug loading capacity in liposomal formulations without compromising stability. Additionally, advancements in nanotechnology have enabled the development of multifunctional liposomes capable of triggered release and personalized drug delivery. These delivery systems have dramatically improved the drug's safety profile by reducing nephrotoxicity and enhancing tissue targeting. The improved tolerability has enabled wider clinical adoption, particularly among immunocompromised patients suffering from invasive fungal infections. Liposomal Amphotericin B, in particular, has become the preferred formulation in many regions, fueling market expansion.

Download Free Sample Report

Key Market Challenges

Toxicity and Adverse Side Effects

One of the most critical challenges impeding the growth of the global Amphotericin B market is the drug's well-documented profile of toxicity and adverse side effects. While Amphotericin B remains a gold standard for treating severe fungal infections, its clinical use is often limited by significant safety concerns, particularly nephrotoxicity, which can lead to acute kidney injury in a substantial proportion of patients. Other frequent adverse effects include infusion-related reactions such as fever, chills, hypotension, and electrolyte imbalances. These complications necessitate intensive patient monitoring and hospitalization, thereby increasing the overall cost and complexity of treatment.

Although the development of liposomal and lipid-based formulations has helped reduce some of these toxicities, their high cost restricts widespread adoption, particularly in resource-limited settings. The ongoing challenge of balancing efficacy with safety continues to be a key concern for healthcare providers and pharmaceutical manufacturers, underscoring the urgent need for safer, equally effective alternatives or improved formulations within the antifungal therapeutics landscape.

Key Market Trends

Increasing Prevalence of Fungal Infections

The rising prevalence of fungal infections globally has emerged as a defining trend in the growth of the Amphotericin B market. Global estimates indicate that invasive fungal infections occur at a rate of approximately 6.5 million cases annually, contributing to around 3.8 million deaths. Of these, an estimated 2.5 million fatalities—representing 68% (ranging between 35% and 90%)—are directly caused by the infections. Invasive aspergillosis alone affects over 2.1 million individuals each year, primarily among patients with chronic obstructive pulmonary disease (COPD), those in intensive care units, and individuals with hematologic malignancies or lung cancer. The condition is associated with a concerning mortality rate of 85.2%. With an increasing number of individuals affected by opportunistic and invasive fungal diseases, the demand for potent antifungal therapies like Amphotericin B has seen a substantial upswing.

This trend is particularly pronounced among immunocompromised populations, including patients with HIV/AIDS, cancer, diabetes, and those undergoing organ transplants or intensive care treatment. In recent years, the global burden of systemic fungal infections such as aspergillosis, candidiasis, and cryptococcosis has grown considerably. These infections, often life-threatening when left untreated, require rapid and aggressive antifungal intervention. Amphotericin B, known for its broad-spectrum efficacy and clinical reliability, continues to be the drug of choice in severe cases, especially in hospital and critical care settings.

Segmental Insights

Sales Channel Insights

Based on Sales Channel, Direct have emerged as the fastest growing segment in the Global Amphotericin B Market in 2024. One of the key factors fueling this trend is the growing preference of hospitals, government health agencies, and large-scale healthcare providers to procure antifungal medications directly from manufacturers. This approach minimizes the risks associated with counterfeit or substandard products, ensures cold chain integrity for temperature-sensitive formulations (such as liposomal Amphotericin B), and facilitates direct technical support, which is often required when handling complex injectable therapies.

End Use Insights

Based on End Use, Systemic Fungal Infections have emerged as the fastest growing segment in the Global Amphotericin B Market during the forecast period. One of the primary drivers behind this trend is the increasing prevalence of immunocompromising conditions such as HIV/AIDS, cancer, diabetes, and organ transplantation, all of which heighten susceptibility to invasive fungal infections like cryptococcosis, aspergillosis, and mucormycosis. Amphotericin B, known for its broad-spectrum activity and fungicidal properties, remains a critical therapeutic agent in managing these complex infections. In addition, outbreaks of opportunistic fungal infections linked to COVID-19, particularly mucormycosis, have significantly heightened global demand for Amphotericin B, especially in countries such as India.

Download Free Sample Report

Regional Insights

Based on Region, Asia Pacific have emerged as the dominating region in the Global Amphotericin B Market in 2024. The region has witnessed a surge in fungal infections, particularly among individuals with HIV/AIDS, cancer, diabetes, and organ transplant recipients—all of whom are highly susceptible to opportunistic fungal diseases. Countries such as India and China report high infection rates, which has significantly increased the consumption of antifungal therapies, including Amphotericin B. The region is home to some of the world’s most cost-efficient pharmaceutical manufacturing hubs, particularly in India, which supplies Amphotericin B both to domestic markets and for export. Lower labor costs, established API production infrastructure, and supportive regulatory frameworks have allowed manufacturers in Asia-Pacific to produce the drug at scale and at competitive prices.

Recent Development

• In February 2025, the WHO Academy launched a new course focused on the management of cryptococcal disease in individuals living with HIV. The course equips healthcare professionals with the essential knowledge to deliver high-quality care to patients with cryptococcal meningitis. Upon successful completion, participants will be able to articulate the proper method for reconstituting and administering liposomal amphotericin B. This training reflects an updated WHO recommendation based on findings from a multicenter randomized controlled trial, which demonstrated that a simplified treatment regimen—consisting of a single high dose of liposomal amphotericin B in combination with flucytosine and fluconazole—is equally effective as the previous standard of care, while offering the advantages of reduced toxicity and minimized monitoring requirements.
• In 2024, Baxter International Inc., a global leader in injectables, anesthesia, and drug compounding, announced the continued expansion of its Pharmaceuticals portfolio with the launch of five new injectable products in the U.S. market. This strategic move reinforces Baxter’s commitment to delivering differentiated and high-quality therapies that meet critical, unmet patient needs. The newly introduced products target key therapeutic areas, with a particular focus on anti-infective and anti-hypotensive treatments, including the well-established antifungal agent Amphotericin B. Through these launches, Baxter continues to strengthen its position as a trusted provider of essential hospital-based pharmaceuticals.
• In September 2024, F2G Ltd—a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for life-threatening rare fungal infections with significant unmet medical need—announced the successful completion of a USD 100 million financing round. Additionally, the company has launched a global Phase 3 clinical trial, known as “OASIS,” to evaluate the efficacy of olorofim in comparison to liposomal amphotericin B followed by standard of care (SOC) in patients with invasive fungal disease caused by confirmed Invasive Aspergillus or probable lower respiratory tract infections due to Aspergillus species.
• In April 2024, Micro-8 announced a new initiative to investigate the regulation of pathogens in space. The study focuses on Candida albicans, a common opportunistic yeast pathogen and widely used model organism in scientific research. Under normal conditions, C. albicans coexists harmlessly within the human microbiome. However, when the immune system is compromised—particularly during extended space missions—it can proliferate uncontrollably and potentially lead to infection. As part of the upcoming cellular growth experiments aboard the International Space Station, the Micro-8 investigation aims to better understand and mitigate such risks. Preliminary findings revealed that C. albicans not only adopts a more elongated cellular form and altered colony structure in space but also exhibits heightened resistance to the antifungal agent Amphotericin B. These adaptations may collectively enhance the pathogen’s infectious potential, underscoring the importance of developing targeted countermeasures in space environments.

Key Market Players

• Xiamen Neore Pharmaceutical Technology Co., Ltd
• Concord Biotech Limited
• United Biotech Pvt Ltd
• Hubei Aoks Bio-Tech Co.,Ltd
• Synbiotics Limited
• North China Pharmaceutical Huasheng Co., Ltd
• Xi'an Sonwu Biotech Co., Ltd.
• Century Pharmaceutical Ltd
• Xellia Pharmaceuticals

Report Scope

In this report, the Global Amphotericin B Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Amphotericin B Market, By Sales Channel:

o   Direct

o   Indirect

• Amphotericin B Market, By End Use:

o   Systemic Fungal Infections

o   Candidiasis

o   Aspergillosis

o   Mucormycosis

o   Leishmaniasis

o   Others

• Amphotericin B Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Amphotericin B Market.

Available Customizations:

Global Amphotericin B Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Amphotericin B Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]